|
1
|
McDavid K, Lee J, Fulton JP, Tonita J,
Thompson TD, Ferlay J, Brawley O and Bray F: Prostate cancer
incidence and mortality rates and trends in the United States and
Canada. Public Health Rep. 119:174–186. 2004.PubMed/NCBI
|
|
2
|
Bono AV: The global state of prostate
cancer: Epidemiology and screening in the second millennium. BJU
Int. 94:(Suppl 3). S1–S2. 2004. View Article : Google Scholar
|
|
3
|
Torre LA, Sauer AM, Chen MS Jr,
Kagawa-Singer M, Jemal A and Siegel RL: Cancer statistics for Asian
Americans, Native Hawaiians, and Pacific Islanders, 2016:
Converging incidence in males and females. CA Cancer J Clin.
66:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kontos CK, Adamopoulos PG and Scorilas A:
Prognostic and predictive biomarkers in prostate cancer. Expert Rev
Mol Diagn. 15:1567–1576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chao OS and Clément MV: Epidermal growth
factor and serum activate distinct pathways to inhibit the BH3 only
protein BAD in prostate carcinoma LNCaP cells. Oncogene.
25:4458–4469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen S, Niu Y, Lee SO and Chang C: Androgen
receptor (AR) positive vs negative roles in prostate cancer cell
deaths including apoptosis, anoikis, entosis, necrosis and
autophagic cell death. Cancer Treat Rev. 40:31–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coppola D, Oliveri C, Sayegh Z, Boulware
D, Takahashi Y, Pow-Sang J, Djeu JY and Wang HG: Bax-interacting
factor-1 expression in prostate cancer. Clin Genitourin Cancer.
6:117–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castilla C, Congregado B, Chinchón D,
Torrubia FJ, Japón MA and Sáez C: Bcl-xL is overexpressed in
hormone-resistant prostate cancer and promotes survival of LNCaP
cells via interaction with proapoptotic Bak. Endocrinology.
147:4960–4967. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shukla S, Fu P and Gupta S: Apigenin
induces apoptosis by targeting inhibitor of apoptosis proteins and
Ku70-Bax interaction in prostate cancer. Apoptosis. 19:883–894.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Bi L, Ye Y and Chen J:
Formononetin induces apoptosis in PC-3 prostate cancer cells
through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt
pathway. Nutr Cancer. 66:656–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi Y, Meyerkord CL and Wang HG:
Bif-1/endophilin B1: A candidate for crescent driving force in
autophagy. Cell Death Differ. 16:947–955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schlauder SM, Calder KB, Khalil FK,
Passmore L, Mathew RA and Morgan MB: Bif-1 and Bax expression in
cutaneous Merkel cell carcinoma. J Cutan Pathol. 36:21–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cuddeback SM, Yamaguchi H, Komatsu K,
Miyashita T, Yamada M, Wu C, Singh S and Wang HG: Molecular cloning
and characterization of Bif-1. A novel Src homology 3
domain-containing protein that associates with Bax. J Biol Chem.
276:20559–20565. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi Y, Karbowski M, Yamaguchi H,
Kazi A, Wu J, Sebti SM, Youle RJ and Wang HG: Loss of Bif-1
suppresses Bax/Bak conformational change and mitochondrial
apoptosis. Mol Cell Biol. 25:9369–9382. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coppola D, Khalil F, Eschrich SA, Boulware
D, Yeatman T and Wang HG: Down-regulation of Bax-interacting
factor-1 in colorectal adenocarcinoma. Cancer. 113:2665–2670. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JW, Jeong EG, Soung YH, Nam SW, Lee
JY, Yoo NJ and Lee SH: Decreased expression of tumour suppressor
Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric
carcinomas. Pathology. 38:312–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan R, Miao Y, Shan X, Qian H, Song C, Wu
G, Chen Y and Zha W: Bif-1 is overexpressed in hepatocellular
carcinoma and correlates with shortened patient survival. Oncol
Lett. 3:851–854. 2012.PubMed/NCBI
|
|
19
|
Iacopino F, Angelucci C, Lama G, Zelano G,
La Torre G, D'Addessi A, Giovannini C, Bertaccini A, Macaluso MP,
Martorana G, et al: Apoptosis-related gene expression in benign
prostatic hyperplasia and prostate carcinoma. Anticancer Res.
26:1849–1854. 2006.PubMed/NCBI
|
|
20
|
Runkle KB, Meyerkord CL, Desai NV,
Takahashi Y and Wang HG: Bif-1 suppresses breast cancer cell
migration by promoting EGFR endocytic degradation. Cancer Biol
Ther. 13:956–966. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mendonca MS, Howard KL, Farrington DL,
Desmond LA, Temples TM, Mayhugh BM, Pink JJ and Boothman DA:
Delayed apoptotic responses associated with radiation-induced
neoplastic transformation of human hybrid cells. Cancer Res.
59:3972–3979. 1999.PubMed/NCBI
|
|
22
|
Bonner AE, Lemon WJ, Devereux TR, Lubet RA
and You M: Molecular profiling of mouse lung tumors: Association
with tumor progression, lung development, and human lung
adenocarcinomas. Oncogene. 23:1166–1176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coppola D, Helm J, Ghayouri M, Malafa MP
and Wang HG: Down-regulation of Bax-interacting factor 1 in human
pancreatic ductal adenocarcinoma. Pancreas. 40:433–437. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho J, Kong JW, Choong LY, Loh MC, Toy W,
Chong PK, Wong CH, Wong CY, Shah N and Lim YP: Novel breast cancer
metastasis-associated proteins. J Proteome Res. 8:583–594. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ko YH, Cho YS, Won HS, An HJ, Sun DS, Hong
SU, Park JH and Lee MA: Stage-stratified analysis of prognostic
significance of Bax-interacting factor-1 expression in resected
colorectal cancer. Biomed Res Int. 2013:3298392013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SY, Oh YL, Kim KM, Jeong EG, Kim MS,
Yoo NJ and Lee SH: Decreased expression of Bax-interacting factor-1
(Bif-1) in invasive urinary bladder and gallbladder cancers.
Pathology. 40:553–557. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoimes CJ and Kelly WK: Redefining hormone
resistance in prostate cancer. Ther Adv Med Oncol. 2:107–123. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang DB, Uo T, Kinoshita C, Sopher BL, Lee
RJ, Murphy SP, Kinoshita Y, Garden GA, Wang HG and Morrison RS: Bax
interacting factor-1 promotes survival and mitochondrial elongation
in neurons. J Neurosci. 34:2674–2683. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang J, Takahashi Y, Cheng E, Liu J,
Terranova PF, Zhao B, Thrasher JB, Wang HG and Li B: GSK-3beta
promotes cell survival by modulating Bif-1-dependent autophagy and
cell death. J Cell Sci. 123:861–870. 2010. View Article : Google Scholar : PubMed/NCBI
|
